EXPERIENCE. CONSISTENCY. SUPPORT.

For more than 18 years,1 patients and their healthcare providers have trusted Remodulin to help reduce PAH symptoms and help patients have more active lives.

United Therapeutics has been consistently manufacturing Remodulin since its introduction in 2002. During that time, there have been no supply interruptions for Remodulin, due to our commitment to hold a 2-year supply of inventory at all times.

Our story

Remodulin is produced by United Therapeutics Corporation, a medical biotechnology company, founded by Martine and Bina Rothblatt in 1996, after their daughter’s PAH was diagnosed. United Therapeutics was born from a very personal and passionate desire to develop medicines that could help their daughter and others suffering from this rare disease.

United Therapeutics is committed to innovation in the treatment of PAH and helping patients live with PAH. United Therapeutics supports HCPs and patients who are being treated with branded Remodulin with support programs, such as SPmix, financial assistance, referral support, and Specialty Pharmacy nursing support.

WHY REMODULIN?

Experience

18 years of clinical experience1

Consistency

No supply interruptions since launch in 2002

Support

United Therapeutics provides support for your patients

Ensure your patient receives your choice of treatment

When you want to ensure patients receive Remodulin, indicate “Dispense as Written, Brand Medically Necessary, and No Substitution” in the space provided on the PAH Referral Form as shown in the example below.

PLEASE NOTE: The rules for writing DAW will vary by state. Our DAW Requirements Guide can help you find your specific state or territory requirements. Be sure to include the required language for your state to ensure that branded product is dispensed.

Referral Form Signature Example

Contact UTAssist to help eligible patients obtain access to their prescribed therapies.

State’s or territory’s DAW requirements

A state’s or territory’s DAW requirements may help you preserve your choice for branded medication if you decide that it is the right option for your patients.

Specific wording for DAW may vary by state, such as “Brand Medically Necessary” and “Do Not Substitute.”

Use our DAW Requirements Guide to find your specific state or territory requirements.

DAW=dispense as written; PAH=pulmonary arterial hypertension.

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Reference: 1. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2018.